Education
About Us
Working with TipRanks
Follow Us
Insmed (INSM)
NASDAQ:INSM
INSM Stock Chart & Stats
$147.00
-$1.02(-1.54%)
At close: 4:00 PM EST
$147.00
-$1.02(-1.54%)
Day’s Range― - ―
52-Week Range$60.40 - $212.75
Previous CloseN/A
Volume462.72K
Average Volume (3M)2.28M
Market Cap
$31.69B
Enterprise Value$31.80B
Total Cash (Recent Filing)$1.43B
Total Debt (Recent Filing)$768.16M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Apr 30, 2026EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding215,551,900
10 Day Avg. Volume2,503,371
30 Day Avg. Volume2,277,205
Financial Highlights & Ratios
PEG Ratio-1.93
Price to Book (P/B)50.31
Price to Sales (P/S)61.31
P/FCF Ratio-38.43
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue52.44
Enterprise Value/Gross Profit66.04
Enterprise Value/Ebitda-27.04
Forecast
1Y Price Target
$214.44Price Target Upside45.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-2.71
Revenue Forecast (FY)$1.62B
Bulls Say, Bears Say
Bulls Say
Commercial Launch And GuidanceManagement's first formal revenue guidance for Brinsupri combined with strong initial uptake and favorable payer access signals clearer commercial traction and potential for higher-than-expected net sales.
Indication Expansion And Addressable MarketEvidence of overlap between bronchiectasis, COPD, and asthma suggests that identifying undiagnosed bronchiectasis in these patients and expanding Brinsupri's label could materially increase the treatable population.
Pipeline Differentiation And Regulatory PathwayTPIP's once-daily dry-powder formulation, potential for longer-acting pulmonary vasodilation, and orphan designation with a streamlined late-stage requirement create a favorable pathway to differentiate and accelerate commercial return.
Bears Say
International Expansion ConstraintsPausing ex‑U.S. Brinsupri launches pending clarity on most-favored-nation policy limits international revenue opportunities and concentrates the company's near-term growth risk in the US market.
Investor Confidence And Clinical Program RiskPersistent investor uncertainty about the sustainability of Brinsupri's sales trajectory and the risk of setbacks in major clinical programs could keep sentiment muted and impede a favorable re-rating.
Operating Expenses And Profitability PressureHigher research and development and selling expenses tied to manufacturing, in‑licensing, and launch preparation have widened operating losses and increase near-term pressure on profitability.
Insmed News
INSM FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was $60.40 and its highest was $212.75 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is $31.69B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Apr 30, 2026 which is in 56 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Feb 19, 2026. The company reported -$1.54 earnings per share for the quarter, missing the consensus estimate of -$1.072 by -$0.468.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -0.99.
How many shares outstanding does Insmed have?
Insmed has 215,551,900 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -$1.54 in its last earnings report, missing expectations of -$1.072. Following the earnings report the stock price went up 6.545%.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in INSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$214.44 (45.88% Upside)
$214.44 (45.88% Upside)
Blogger Sentiment
Bullish
INSM Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
79.42%
12-Months-Change
Fundamentals
Return on Equity
-249.28%
Trailing 12-Months
Asset Growth
11.82%
Trailing 12-Months
Company Description
Insmed
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
INSM Company Deck
INSM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strongly positive commercial momentum driven by Brinsupri's launch (first full-quarter net revenue of $144.6M and guidance of at least $1B in 2026), solid ARIKAYCE growth (Japan +40% YoY) and a strong balance sheet (~$1.4B cash). Clinical progress (TPIP orphan designation and planned Phase III) and pipeline expansion via acquisitions were additional positives. Near-term challenges noted include early-stage depth of prescribing, some payer documentation requirements and increased operating spend (including ~$70M of one-time Q4 cash items). Management believes these lowlights are manageable and reiterated a path to cash flow positivity while retaining flexibility for selective business development. On balance, the highlights materially outweigh the lowlights.View all INSM earnings summariesINSM Stock 12 Month Forecast
Average Price Target
$214.44
▲(45.88% Upside)
Technical Analysis
Ownership Overview
0.79% Insiders
31.27% Mutual Funds
6.58% Other Institutional Investors
41.59% Public Companies and Individual Investors